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Abstract
Background: To test if early-cleavage was a strong predictor of pregnancy in patients receiving
either a GnRH agonist long protocol or a GnRH antagonist protocol for in-vitro fertilization
treatment (IVF) and intracytoplasmic sperm injection (ICSI).
Methods: This retrospective study included 534 patients undergoing a fresh cycle of oocyte
retrieval and the day-3 embryo transfer (from 22 to 46 years old). Of the 534 patients treated, 331
received a GnRH agonist long stimulation protocol (GnRH agonist group) for ovarian stimulation
and 203 patients received a GnRH antagonist protocol (GnRH antagonist group). In each group,
patients who had at least one early-cleavage embryo transferred were designated as the 'early-
cleavage' subgroup. Patients who had no early-cleavage embryos transferred were designated as
the 'late-cleavage' subgroup.
Results: The early cleavage rate was significantly lower in the GnRH antagonist group compared
with that in the GnRH agonist group (IVF cycles: 34% versus 20%; ICSI cycles: 50% versus 37.8%,
respectively, P < 0.0001). In the GnRH agonist group, the pregnancy rates were significantly higher
in the early-cleavage subgroup than those in the late-cleavage subgroup (53.7% vs 33.9%, P <
0.0001). In the GnRH antagonist group, the pregnancy rates were not significantly different
between the early-cleavage and late-cleavage subgroups (45.9% vs 43.8%, P > 0.05).
Conclusion: Early cleavage of zygote is not a reliable predictor for embryo implantation potential
in using the GnRH antagonist protocol. Furthermore, the implantation rates between the GnRH
agonist and GnRH antagonist groups were comparable.
Background
In order to reduce multiple pregnancies and achieve a
maximal rate of implantation, selection of the most viable
embryo for transfer has become a high priority in assisted
reproduction treatment. Traditionally, embryo selection is
performed by using embryo morphology as the guideline.
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Other additional selection methods include oocyte and
zygote morphology, blastomere symmetry and blastocyst
culture. Recently, observation of embryonic first mitosis
has been emphasized. Several studies have shown that
embryonic early cleavage, which occurs at 25–27 hours
post insemination for in vitro fertilization (IVF)/intracyto-
plasmic sperm injection (ICSI), can be an additional indi-
cator of viable embryos [1-6]. Most of these previous
studies were only using the gonadotrophin-releasing hor-
mone (GnRH) agonist long protocol for pituitary suppres-
sion.
Recently, a GnRH antagonist protocol has become availa-
ble in assisted reproduction therapy. The advantages of
GnRH antagonist are associated with a lower consump-
tion of gonadotropins, a shorter duration of stimulation,
a lower risk of ovarian hyperstimulation syndrome
(OHSS) [7], and a lower cancellation rate, especially in
poor responders [8-10]. Previous studies have shown that
using the GnRH antagonist protocol had the comparable
pregnancy rate compared with the GnRH long agonist
protocol [8-10]. However, some studies have shown that
GnRH receptors are expressed in human and mouse pre-
implantation embryos [11,12], and addition of GnRH
antagonist to mouse embryo culture media inhibits pre-
implantation embryo development [11]. We wondered
whether the effects of these two different protocols upon
embryonic development were the same. In our previous
study, we had found that early-cleavage is not a reliable
predictor for embryo implantation in women over 35
years old using the GnRH antagonist protocol [13]. In this
study, we recruited women without age limitation to
investigate if early-cleavage is a good predictor for their
pregnancy under the treatment of GnRH antagonists.
Therefore, the aim of this study was to compare the
embryonic early-cleavage rates between the GnRH agonist
and GnRH antagonist groups and to investigate if early-
cleavage was a good predictor for IVF outcome in both
groups.
Methods
Study subjects
This study was a retrospective study of IVF/ICSI outcome
based on the medical records of patients in the Fertility
Unit of MacKay Memorial Hospital from the time period,
January 2004 to December 2006. The study protocol was
approved by the Institutional Review Board of MacKay
Memorial Hospital in Taipei, Taiwan.
Ovarian stimulation protocols
Two stimulation protocols were used in this study; the
GnRH agonist long protocol (GnRH agonist group) and
the GnRH antagonist protocol (GnRH antagonist group).
In the GnRH agonist group, leuprolide acetate (Takeda
Pharma GmbH, Stolberg, Germany) was given at a daily
dose of 1 mg, starting on day 21 of the previous cycle.
Once serum levels of E2 < 30 pg/ml were achieved, the
daily dose of leuprolide acetate was reduced to 0.5 mg.
Recombinant follicle-stimulating hormone (FSH; Gonal-
F; Serono Laboratories, Aubonne, Switzerland) and
human menopausal gonadotropin (hMG; Menopur; Fer-
ring GmbH, Kiel, Germany) were given until the day of
hCG administration. The doses were adjusted according
to the patient's ovarian response. In the GnRH antagonist
group, recombinant FSH and hMG were administrated
daily from the second day of the menstrual cycle. The
doses were also adjusted according to the patient's indi-
vidual ovarian response. Once the dominant follicle
reached 14 mm in mean diameter, cetrorelix (Cetrotide;
Serono, Baxter Oncology GmbH, Halle, Germany) was
administered subcutaneously at a dose of 0.25 mg daily
until the day of hCG administration.
In both groups, 10,000 IU hCG (Profasi; Serono Labora-
tories, Aubonne, Switzerland) was administered when at
least two follicles reached 18 mm in diameter, and oocyte
retrieval was performed 34–36 hours later. Upon comple-
tion of oocyte collection and IVF/ICSI, embryos were
graded morphologically by the same embryologist.
Embryo transfer was performed 72 hours after the oocyte
retrieval. In each stimulation protocol, patients who had
at least one early-cleavage embryo transferred were desig-
nated as the 'early-cleavage' subgroup. Patients who had
no early-cleavage embryos transferred were designated as
the 'late-cleavage' subgroup.
The luteal phase was supported by vaginal supplementa-
tion of 200 mg micronized natural progesterone (Progef-
fik; Effik, Paris, France) three times a day. To assess
treatment outcome, serum hCG was measured 14 days
after oocyte retrieval. An increase of serum hCG to levels
above 50 IU/l indicated pregnancy.
To minimize confounding factors, patients diagnosed
with polycystic ovaries, a severely poor response (fewer
than two retrieved oocytes and an E2 level ≤ 300 pg/ml on
the day of human chorionic gonadotrophin (hCG)
administration), and cycles for oocyte donation were
excluded from the study. Only patients undergoing their
first stimulated cycle were included and only one treat-
ment cycle per patient was analyzed. A total of 534
embryo transfer cycles (from 22 to 46 years old) were
included in this study. There were 331 cycles treated with
an agonist protocol (192 cycles from IVF while 139 cycles
for ICSI) and the other 203 cycles treated with an antago-
nist protocol (116 cycles from IVF while 87 cycles from
ICSI). Patients with male factor infertility (which was
defined by the presence of any of the following parame-
ters: sperm concentration < 20 × 106/ml, motility < 50%,
and normal morphology < 15%) were treated with ICSI,Reproductive Biology and Endocrinology 2009, 7:20 http://www.rbej.com/content/7/1/20
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while others without male factor infertility were treated
with conventional insemination for IVF.
Insemination and ICSI
Conventional IVF or ICSI was performed 3–5 h after
oocyte aspiration. For conventional IVF, each oocyte was
inseminated with 20 × 103 motile spermatozoa in a single
drop of 20 μl medium (Quinn's Advantage Fertilization
medium; SAGE IVF Inc. Trumbull, Connecticut, U.S.A.).
For the ICSI procedure, 1–2 μl washed spermatozoa were
placed in 7% polyvinylpyrrolidone (PVP; SAGE IVF Inc.)
and injected using standard techniques. Each embryo was
cultured in a single drop of 20 μl medium (Quinn's
Advantage Cleavage medium; SAGE IVF Inc.) supple-
mented with 10% synthetic serum substitute (Quinn's
Advantage Serum Protein Substitute; SAGE IVF Inc.) cov-
ered with mineral oil (SAGE IVF Inc.) in an atmosphere of
5% O2, 5% CO2 and 90% N2 at 37°C.
Assessment of fertilization, early cleavage and embryo 
quality
Normal fertilization was confirmed by the presence of two
pronuclei and two polar bodies 16–20 h (day1) after
insemination for IVF or ICSI. On the same day, early
cleavage examination was performed 25–27 hours after
insemination. Embryos displaying two cells at inspection
were designated as 'early cleavage'. The embryos that had
not yet cleaved to the 2-cell stage were designated as 'late
cleavage'. Embryos were further examined for their quality
at 44–46 hours (day 2) and at 66–68 hours (day 3). The
day 2 and day 3 embryo scoring system (modified from
Veeck [14]) was as follows: for day 2 embryos, namely:
score 1: embryo with blastomeres of equal size and no
cytoplasmic fragmentation; score 2: embryo with blast-
omeres of equal or unequal size and cytoplasmic fragmen-
tation ≤ 10% of the embryo surface; score 3: embryo with
blastomeres of equal or unequal size and 11%–49% over-
all cytoplasmic fragmentation; score 4: embryo with blas-
tomeres of equal or unequal size and cytoplasmic
fragmentation ≥ 50% of the embryo surface. For the day 3
embryo scoring system, this was the same as described
above except score 2 denotes ≤20% cytoplasmic fragmen-
tation and score 3 denotes 21%–49% cytoplasmic frag-
mentation.
Statistical analysis
Statistical analysis was performed using SPSS software ver-
sion 12.0 for Windows (Statistical Package for Social Sci-
ences, Inc., USA). The differences of means between two
variables were calculated using the Mann-Whitney U test.
The differences in binary variables were calculated using
the chi-square test. A P value of < 0.05 was considered sta-
tistically significant.
Results
A total of 534 treatment cycles were analyzed. Of these,
331 cycles were from the agonist group (192 cycles from
IVF and 139 cycles from ICSI) while 203 cycles were from
the antagonist group (116 cycles from IVF and 87 cycles
from ICSI). Cycle characteristics of the agonist and antag-
onist groups are given in Table 1. The percentages of good
quality of embryos (grade 1 and grade 2 embryos) derived
from IVF and ICSI were no significantly different in both
agonist and antagonist groups. The mean duration of
stimulation was significantly shorter in the GnRH antago-
nist group compared with that in the GnRH agonist group
(9.9 ± 0.1 vs.11.3 ± 0.1, P < 0.05). The E2 levels on the day
of hCG injection were significantly lower in the GnRH
antagonist group than those in the GnRH agonist group
(1731.5 ± 81.1 vs. 2347.8 ± 71.9, P < 0.0001). Further-
more, the early cleavage rate was significantly lower in the
GnRH antagonist group compared with that in the GnRH
agonist group (IVF cycles: 34% versus 20%; ICSI
cycles:50% versus 37.8%, respectively, P < 0.0001).
A total of 3425 embryos were analyzed; 2259 embryos
were from the agonist group and 1166 embryos were from
the antagonist group. In the agonist group, 926 (41%) of
2259 embryos were early-cleavage embryos, and the
remaining 1333 (59%) embryos were late-cleavage
embryos. There were significant differences in the day 2
and day 3 embryo scores and mean numbers of blast-
omeres between the early and late-cleavage embryo sub-
groups (Table 2). In the agonist group, 216 cycles had at
least one early-cleavage embryo for transfer while the
remaining 115 cycles had all late-cleavage embryos for
transfer. The pregnancy rate was significantly higher in the
early-cleavage subgroup then that in the late cleavage sub-
group (53.7% vs. 33.9%, P < 0.0001) (Table 2).
In the antagonist group, 323 (27.7%) of 1166 embryos
were early-cleavage embryos while the remaining 843
(72.3%) embryos were late-cleavage embryos. There were
no significant differences in the day 2 and day 3 embryo
scores or in the day 3 numbers of blastomeres between the
early and late-cleavage embryo subgroups in the antago-
nist group (1.92 ± 0.04 vs. 2.11 ± 0.04, 2.02 ± 0.06 vs.
2.10 ± 0.06, and 7.29 ± 0.10 vs. 7.18 ± 0.10, P > 0.05)
(Table 3). In the antagonist group, 98 cycles had at least
one early-cleavage embryo for transfer while the remain-
ing 105 cycles had all late-cleavage embryos for transfer.
There was no significant difference in pregnancy rate
between the early-cleavage and late-cleavage subgroups
(45.9% vs. 43.8%, P > 0.05) (Table 3).
Discussion
In the present study, we observed that embryonic early
cleavage rate was significantly lower in the GnRH antago-
nist protocol compared with that in the GnRH long ago-Reproductive Biology and Endocrinology 2009, 7:20 http://www.rbej.com/content/7/1/20
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nist protocol (27.7% vs. 41%, P < 0.0001). Although
fewer oocytes were obtained in the GnRH antagonist
groups, the mean numbers of normal fertilized oocytes,
implantation rate, and ongoing pregnancy rate were all
comparable with those in the GnRH agonist group. Con-
sistent with previous studies [1-6], we also observed that
embryonic early-cleavage was a good predictor for early
embryonic development and pregnancy outcome in using
a GnRH agonist long protocol (Table 2). However, these
relationships were not found in using the GnRH antago-
nist protocol (Table 3).
To achieve a singleton pregnancy without reducing the
implantation rate should be the primary goal in assisted
reproduction treatment. Up to now, embryonic morphol-
ogy has been one of the most useful tools to achieve this
Table 1: Comparisons of cycle characteristics in the agonist and the antagonist groups.
Agonist group Antagonist group P value
No. of cycles 331 203
ICSI rate 42% (139/331) 43% (87/203) NS
Age of patients 33.9 ± 0.2 (22–45) 34.4 ± 0.3 (26–46) NS
Duration of stimulation (days) 11.3 ± 0.1 9.9 ± 0.1 < 0.05
No. of ampoules used per cycle 38.6 ± 0.5 35.4 ± 0.4 NS
Peak E2 level 2347.8 ± 71.9 1731.5 ± 81.1 < 0.0001
No. of oocytes retrieved per cycle 10.0 ± 0.3 8.2 ± 0.4 < 0.05
No. of mature oocytes per cycle 9.0 ± 0.3 7.2 ± 0.3 < 0.05
No. of normal fertilized oocytes per cycle 6.1 ± 0.3 (2019) 5.7 ± 0.3 (1157) NS
Total no. of embryos 2259 1166
Good embryo rate
IVF 54.6% (715/1309)a 56.5%(375/664)c
ICSI 54.4% (517/950)b 56% (281/502)d
No. of embryo transfer 3.8 ± 0.1 3.32 ± 0.9 NS
Embryonic early cleavage rate
IVF 34% (450/1309) 20% (133/664) < 0.0001
ICSI 50% (476/950) 37.8% (190/502) < 0.0001
Pregnancy rate (%)
IVF 46.9% (90/192) 44.8% (52/116) NS
ICSI 46.8% (65/139) 44.8% (39/87) NS
Implantation rate
IVF 21.9% (160/730) 19% (73/384) NS
ICSI 21.2% (112/528) 18.9% (55/290) NS
On going pregnancy rate
IVF 35.9% (69/192) 38.8% (45/116) NS
ICSI 36% (50/139) 39% (34/87) NS
Note: Values are the mean ± SEM. NS: no significance.
a versus
b: NS.
cversusd: NS.
Table 2: Embryo scores and mean numbers of blastomeres of the early-cleavage and late-cleavage subgroups in the agonist group.
Early-cleavage subgroup Late-cleavage subgroup P value
Day 2 embryo score 1.8 ± 0.03 2.1 ± 0.03 < 0.0001
No. of day 2 blastomeres 4.0 ± 0.04 3.17 ± 0.04 < 0.0001
Day 3 embryo score 1.9 ± 0.03 2.5 ± 0.03 < 0.0001
No. of day 3 blastomeres 7.28 ± 0.06 6.16 ± 0.06 < 0.0001
Pregnancy rate (%) 116/216 (53.7) 39/115 (33.9) < 0.0001
Note: Values are the mean ± SEM.Reproductive Biology and Endocrinology 2009, 7:20 http://www.rbej.com/content/7/1/20
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goal. In recent years, embryonic early-cleavage observed
25–27 hours after insemination has been suggested as
another available parameter for embryo selection [1-6].
Moreover, all these previous studies had used a GnRH
agonist long protocol for pituitary suppression. In the
present study, we found that embryonic early-cleavage
rate was significantly lower in using the GnRH antagonist
protocol than the agonist protocol. In our previous study
[13], we observed that the early-cleavage rate was signifi-
cantly lower with the GnRH antagonists and was not a
reliable predictor of pregnancy in women older than 35.
In the present study, we also observed this relationship
without any age limitation.
In the present study, the results showed that the early-
cleavage embryos were of better quality and resulted in a
higher pregnancy rate than the late-cleavage embryos in
the GnRH agonist group. This was consistent with previ-
ous studies [1-6]. However, embryo quality and preg-
nancy rate were not significantly different between the
early and late cleavage embryos in the GnRH antagonist
group (Table 3). GnRH antagonists act through competi-
tive binding to GnRH receptors, a situation that can be
reversed by GnRH. Previous studies have shown that con-
tinuous exposure to GnRH antagonists will induce down-
regulation of GnRH receptors and gene expression
[15,16]. With the discovery of extra-pituitary GnRH recep-
tors in reproductive tissues, including the uterus,
endometrium, oocyte-cumulus complex, pre-implanta-
tion embryo and placenta [11,12,17], it is possible that
the use of GnRH antagonists may lead to down-regulation
of the receptors. Several previous studies using cancer cell
lines have investigated the effect of GnRH antagonists at
the cellular level. [18,19] In these in-vitro studies, GnRH
antagonists interfered with cell growth by decreasing the
synthesis of insulin-like growth factor (IGF) and inositol
1, 4, 5-trisphosphate (IP3). Another study showed that a
decrease of epidermal growth factor (EGF) receptor
mRNA and EGF peptide occurs in the presence of GnRH
antagonists in vitro [20]. Both EGF and IGF receptors
form the basis for induction of an important MAP kinase
(MAPK)-mediated mitogenic cascade [21,22]. Based on
the results of the above studies, theoretically, it is possible
that the first mitosis of zygote (early cleavage) could be
retarded if IGF, EGF and the MAPK signal transduction
pathway are inhibited by GnRH antagonists. Another
study showed the presence of GnRH receptor mRNA in
the developing embryo and the pre-implantation embry-
onic development was significantly decreased by GnRH
antagonists [11].
In IVF cycles, administration of GnRH antagonist is sus-
pended once hCG is given, and the embryo is transferred
between 5–7 days after the last dose of GnRH antagonist.
The half-life of GnRH antagonist stated by the manufac-
turer is 30 hours and the time interval between the last
dose of GnRH antagonist and the early cleavage of zygotes
is about 75 to 90 hours. Consequently, the GnRH antago-
nist may still have some effects on delaying the first mito-
sis of zygotes. Moreover, there was also a significant
difference in the day 2 mean numbers of blastomeres
between the early-cleavage and late-cleavage embryos in
the GnRH antagonist group (Table 3). However, in the
following 24 hours the mean numbers of blastomeres on
day 3 were not significantly different between the early-
cleavage and late-cleavage embryos in the GnRH antago-
nist group (Table 3). Furthermore, the average embryo
scores on days 2 and 3 were also not significantly different
between the early-cleavage and late-cleavage embryos in
the GnRH antagonist group (Table 3). Therefore, the
effects of GnRH antagonist on the pre-implantation
embryo may only be limited to the first 2 days after insem-
ination or ICSI. The potential detrimental effects of GnRH
antagonist upon the developing embryo may be signifi-
cantly diminished 2 days after insemination. This could
be the reason for a lack of any significant negative effect of
GnRH antagonists on pregnancy and live birth outcome
[9,10,23,24]. Based on the results in table 3 and previous
reports, early cleavage of zygote is not a reliable predictor
for pregnancy potential in using the GnRH antagonist
protocol.
In the present study, we observed that using the GnRH
antagonist protocol, the mean numbers of obtained
oocytes and mature oocytes were significantly fewer than
using the GnRH long agonist protocol. But the mean
numbers of normal fertilized oocytes, pregnancy rate,
implantation rate, and ongoing pregnancy rate were com-
Table 3: Embryo scores and mean numbers of blastomeres of the early-cleavage and late-cleavage subgroups in the antagonist group.
Early-cleavage subgroup Late-cleavage subgroup P value
Day 2 embryo score 1.92 ± 0.04 2.11 ± 0.04 NS
No of day 2 blastomeres 4.11 ± 0.06 3.21 ± 0.06 < 0.05
Day 3 embryo score 2.02 ± 0.06 2.10 ± 0.06 NS
No. of day 3 blastomeres 7.29 ± 0.10 7.18 ± 0.10 NS
Pregnancy rate (%) 45.9 (45/98) 43.8 (46/105) NS
Note: Values are the mean ± SEM. NS: no significance.Reproductive Biology and Endocrinology 2009, 7:20 http://www.rbej.com/content/7/1/20
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parable between the two groups, which is in concordance
with previous studies [25,26]. Though the GnRH antago-
nist protocol resulted in fewer oocytes, the pregnancy rate
and normal fertilized embryos were comparable with the
GnRH long agonist protocol. These findings might be due
to decreased proportion of aneuploid and mosaic
embryos in the GnRH antagonist protocol and the oocytes
more likely to result in pregnancy were preferentially
selected [25,26].
Conclusion
In conclusion, the results of this study showed that the
early-cleavage rate was significantly lower in the GnRH
antagonist protocol than that in the GnRH long agonist
protocol. Consistent with previous studies, the results of
this study showed that the early-cleavage status of zygotes
is indeed a parameter for embryo selection when using the
GnRH agonist long protocol for ovarian stimulation.
However, the results also showed that early cleavage of
zygote seems not to be a powerful predictor for embryo
implantation potential when the GnRH antagonist proto-
col was applied. Furthermore, despite lower numbers of
oocytes were obtained in the GnRH antagonist protocol,
it still showed comparable implantation rate to the GnRH
agonist protocol.
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